HAS2 and prostate adenocarcinoma: Similarly, HAS2 exhibited significant downregulation in BLCA, BRCA, KICH, KIRC, kidney renal papillary cell carcinoma (KIRP), LIHC, LUAD, LUSC, prostate adenocarcinoma (PRAD), and UCEC tumors.